The market of global vaccine is 2011 strategy trends

The market of global vaccine is 2011 strategy trends Four major factors will be inhibited increasing
Aggravation day by day, researching and developing the shortage of the new products of line on later stage of the competition between control of cost, influenza vaccine, and the strong one opposes the theory inoculated will be key factors influencing vaccine field to continue increasing. The latest analysis from Nature - -

The market of vaccine increases at full speed in the past 5 years. It is reported, global five major pharmacy giants (comparable to the east, Pfizer and Novartis of Philippine Pasteur of the promise, Glenn plain SmithKline, silent sand) The sales amount of the vaccine products has accounted for 80% of the market of whole vaccine, its total sales amount of product of vaccine rises to 20 billion dollars in 2009 from 7,100 million dollars in 2004 too. New the intersection of high price and vaccine list and not great to prevail the intersection of influenza and sale of vaccine promote the intersection of vaccine and powerful behavior of market in recent years. However, the aggravation day by day, researching and developing the shortage of the new products of line on later stage of the competition between control of cost, influenza vaccine, and the strong one opposes the theory inoculated will be key factors influencing vaccine field to continue increasing.

Constantly changeable market of vaccine



Before 2000, pharmacy enterprises and the general view of biotech company thought the income on the market of vaccine was unlikely. But with the further cognition of pathogen biology and human immune system, and more complete vaccine damages and compensates for the setting-up legislating to make the development of vaccine more attractive, thus people's approval of the vaccine advantage increases progressively. Moreover, new vaccine products and adjuvant technology have promoted the high demand to meet the development of the card domain vaccine products.

For example the pneumonia coccus of Pfizer combines vaccine Prevnar, and silent the intersection of sand and the east prevent the intersection of people and papilla of cervical cancer the intersection of tumour and the intersection of virus and four the intersection of price and the intersection of vaccine and the intersection of Gardasil,etc. and new the intersection of high price and success of vaccine these display already getting abundant to prove trader of vaccine The family property is potential ' Table 1) . Pharmacy giant face because the reduced subject problem of income brought in common famous medicine thing competition one after another, and for vaccine products, the threshold of common famous products competition is higher, so vaccine trade has commercial attractiveness even more.

Current situation of market of vaccine



Vaccine is monopolized by five big companies, is comparable to the east of Philippine Pasteur of the promise, silent sand, Glenn plain SmithKline, Pfizer and Novartis after purchasing the favor in 2009 (see Fig. 1) in market . The main vaccine variety includes vaccine of influenza, hepatitis vaccine, children vaccine on the market at present, these products have occupied most share of the global market.

The outburst of H1N1 influenza of 2009, make the income from sales of the vaccine manufacturer of influenza have increase greatly, among them Glenn plain SmithKline, gross sales amount which is comparable to Philippine Pasteur of the promise and three companies of Novartis influenza vaccine reached 6,400 million dollars in 2009 and first half of 2010. However, such a high income may not keep long, the one that it is said the storage level of vaccine of 2010 influenza has greatly glides the phenomenon. In addition, several high-quality new vaccine products behave especially successfully, Prevnar of Pfizer and is silent Gardasil of the east of the sand has already ranked among the ranks of the heavy scale bomb. Have exceeded 1,500 million dollars in the 2009 sales amount of these two products.

New system medicine company



Because of the push of commercial potentiality, vaccine trade has gone through numerous merger and recombination in the past 5 years, pharmacy giant achieve the goal of entering this field or consolidate in status of field this through merger with recombination the ' Table 2) . However, their prospect in this field has nothing in common with each other.

Pfizer has merge and set up the framework of the vaccine field to make with PowderMed and Coley up through 2006, 2007.

Especially after merge the favor in 2009ing, its domain of vaccine is stronger and intacter. Through the merger with the favor, Pfizer has succeeded in obtaining vaccine Prevnar infected to the coccus of pneumonia, and extremely attractive vaccine product line and experienced vaccine research and develop team and sales-force.

In 2007, health, Slay of A, enter the intersection of vaccine and trade too through purchase MedImmune, the intersection of Aris and health obtain nasal cavity give influenza vaccine FluMist of medicine in the purchase. But though health, Slay of A, because influenza erupted and won the unexpected income 2009/2010, but FluMist total sale behaves disappointingly, Slay's health is still a little company in the whole vaccine trade that we think A. The situation of Slay's health is similar with A, Abbott Laboratories Company purchased Solvay in 2009, thus enter the competition ranks of vaccine of influenza, but compared with other companies, still uncompetitive, Abbott Laboratories Company hopes to sell the vaccine business after merging, but not found the appropriate buyer finally. The company of Abbott Laboratories claim to stop most vaccine research and development in September of 2010, while putting main energy into the production of vaccine Influvac of influenza and selling.

The pharmacy giant entering this trade finally is Johson & Johnson, this company purchased Crucell Company with 2,400 million dollars in October of 2010, analyze that thinks vaccine product line and candidate product line of Crucell Company are very attractive, these will further consolidate the position of Johson & Johnson in the field of infectious disease.

In a word, vaccine trade compare with other pharmacy fields, distribute, wait a moment for different fields to be obviously different in clinical research, production, market, so want to succeed in this trade the professional and good development strategy is particularly important.

Light and the new developing market with new target



As basic vaccine is saturated on North American market and European market day by day, company expand to the other areas in order to seek the new development space vaccine one after another. New developing market and developing country become potential focuses that the market of vaccine pays close attention to, because bear at these regional diseases seriously even basic vaccine have a very large space of market, and the local government, for the use and supplying corresponding efforts of vaccine, in addition these favorable factors of waiting a moment are proposed for new developing market and the vaccine trades of developing countries with the increase and increase of medical treatment and health care expenditure of the crowd of middle class Have supported the good development opportunity. The pharmacy local governments and enterprises of countries such as numerous and complicated and Brazil, India, China,etc. of giant enter into cooperation in recent years, in order to expand the new space of market ' Table 3) .

Have lighted and offered the new chance to vaccine developers with new high-efficient price target, industry think B-mode the intersection of meningitis and preventative vaccine become serious scale bomb in the the intersection of stage and the intersection of vaccine and product the next generally, Pfizer and Novartis Company have entered clinical research later stage to the candidate products that will meet the card. Because of able to bear the increase of nature with the bacteriuming, already is the discount directed against medicine greatly for the result of existing antibiotic? Weld and smell of fish dregs of rice salty inferior Ying of Xiang Hua of quiet 's fever for Ba and spit the bag Guo reel silk from cocoons of department of thorax to divine shallowly> Shen shape 4 Where does Quan Xian bright collate racoon dog insane bright mu of the sixth of the twelve Earthly Branches of Die to send Guo Hay 's tired 's magpie's Yong's arm " Hot elaborate the intersection of felt and the intersection of moxibustion and circle sew, regret secretly the intersection of strontium and the intersection of magpie and the intersection of bag and the intersection of Guo and the intersection of Li and in harmony endure the intersection of rake and Hui of Hu the Huaihe River the intersection of and leech Chen Ying Shen evil Gruel hold of Yao way glaze flatter, annotate anxious and fearful drought where collate the intersection of Die and the intersection of the sixth of the twelve Earthly Branches and bones of the body?

April of 2010, U.S.A. FDA has sanctioned the first therapeutic vaccine sipuleucel-T, its goods of cancer vaccine of prostate that it is produced by Dendreon drugmaker are called Provenge. This thus has raised grinding the tide of generating heat of therapeutic vaccine. Therapeutic vaccine that is grinding at present involves Alzheimer's disease, material dependent disease, hepatitis C and HIV in a plurality of fields of infecting etc.. In addition, adjuvant new technology, non- technology of injecting preparations and mucous membrane for medicine technology, and quick flexible production technology, for existing the intersection of children and vaccine and the intersection of influenza and the intersection of vaccine,etc. and the intersection of vaccine and diversification and high-quality to offer more and possible of products.

Vaccine trade prospect



One that is with key product market in fieriness and vaccine trade of the competition is becoming riper, lack new candidate products current situation these, make the intersection of vaccine and trade take, keep growth in the past 10 years have, challenge very much again research and develop, later stage.

The market of the in weight scale bomb Prevnar and Gardasil will be ripe progressively even, such as the following challenges have, store in in the development of new in weight the intersection of scale and the intersection of bomb and the intersection of vaccine and product: Most products, for pathogen apt getting involved vaccine in the market, and there is other only including third hepatitis virus and HIV virus and two kinds to comparatively complicated pathogen vaccine left. Moreover, one and time limit of inoculating that vaccine such as Prevnar, Gardasil, Menactra and RotaTeq all demand to have fast insertion period, compensate for at high price. Meanwhile, influence by economic recession, North America and Europe begin, control to medical cost of expenses already, these cause the drugmaker in order to control and research and develop very difficult reason to redevelop complicated vaccine of the cost. The factor of vaccine inoculation of other restrictions includes: The public breaks into the cognitive weakness, and shortage of cognition of vaccine and correlation technique to epidemic disease.

In addition, because the existing products rely mainly on preventing type to direct against the healthy crowd, so superior security and tolerance are still essential for new candidate products in vaccine is developed.
The market of global vaccine is 2011 strategy trends Four major factors will be inhibited increasing